DKK1 and breast carcinoma: Antibodies that neutralize DKK1 or sclerostin are in trials [54],[55] and may have beneficial effects to relieve the suppression of bone formation caused by these WNT inhibitors, which can be made by breast cancer cells and myeloma as well as by bone (osteocytes in the case of sclerostin).